4-Methyl-4,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),12(16),13-triene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-Methyl-4,9-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),12(16),13-triene
• 化学式: C₁₅H₂₀N₂
• 分子量: 228.33
• InChiKey: YASBOGFWAMXINH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] TREATMENT FOR METHAMPHETAMINE ADDICTION AND REDUCTION OF METHAMPHETAMINE USE USING SEROTONIN ANTAGONISTS<br/>[FR] TRAITEMENT DE L'ACCOUTUMANCE À LA MÉTHAMPHÉTAMINE ET RÉDUCTION DE LA PRISE DE MÉTHAMPHÉTAMINE AU MOYEN D'ANTAGONISTES DE LA SÉROTONINE
  申请人：OMEROS CORP

  公开号：WO2006017861A2

  公开（公告）日：2006-02-16

  Methods for screening specific biological endpoints that can be utilized to identify potential therapeutic agents for METH addiction. In one aspect of the invention, the methods involve reversal of behavioral sensitization and/or conditioned place preference in an animal previously treated with METH in the presence of a known amount of a 5-HT2A/2C antagonist or a selective 5-HT2C antagonist, and reversal of the electrophysiological endpoints in a METH-treated animal in the presence of a known amount of the 5-HT2A/2C antagonist or the selective 5-HT2C antagonist. Therapeutic treatment methods for reversing the set of biological endpoints that change in the METH drug addict using mirtazapine, SDZ SER 082, and related serotonin antagonists are also provided. The methods of the invention may be utilized in the identification of potential new therapies for multiple drugs of abuse.